{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T10:54:21Z","timestamp":1753181661298},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>The purpose of this study was to evaluate the safety and efficacy of intravitreal propranolol for the management of retinal capillary hemangioma in a patient with Von Hippel\u2013Lindau.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Two intravitreal injections of 50 <jats:italic toggle=\"yes\">\u03bc<\/jats:italic>g\/0.05 mL propranolol were administered 6 weeks apart in the left eye of a 26-year-old patient with bilateral multiple retinal capillary hemangiomas. Safety and response to therapy were evaluated using electroretinogram, fluorescein angiography, and measurement of visual acuity. Laser photocoagulation was performed in the right eye.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>One month after the second intravitreal injection of propranolol, fluorescein leakage decreased from the tumors located on the optic nerve head and in the inferonasal retinal periphery. Reduction of the retinal capillary hemangioma vascularity and enhancement of its fibrosis associated with the attenuation of the feeder vessel were also observed. Ophthalmic examination showed no adverse effect except for a mild transient vitreous haziness after each injection. Electroretinogram performed 4 weeks after the first injection revealed no retinal toxicity.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Intravitreal propranolol showed a therapeutic effect on retinal capillary hemangioma with no short-term adverse effects except a mild transient inflammatory response in a patient with Von Hippel\u2013Lindau.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/icb.0000000000000718","type":"journal-article","created":{"date-parts":[[2018,2,21]],"date-time":"2018-02-21T20:19:11Z","timestamp":1519244351000},"page":"305-309","source":"Crossref","is-referenced-by-count":10,"title":["INTRAVITREAL INJECTION OF PROPRANOLOL FOR THE TREATMENT OF RETINAL CAPILLARY HEMANGIOMA IN A CASE OF VON HIPPEL\u2013LINDAU"],"prefix":"10.1097","volume":"14","author":[{"given":"Saeed","family":"Karimi","sequence":"first","affiliation":[{"name":"Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran;"},{"name":"Department of Ophthalmology, Torfeh Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Homayoun","family":"Nikkhah","sequence":"additional","affiliation":[{"name":"Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran;"},{"name":"Department of Ophthalmology, Torfeh Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamid","family":"Ahmadieh","sequence":"additional","affiliation":[{"name":"Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sare","family":"Safi","sequence":"additional","affiliation":[{"name":"Ophthalmic Epidemiology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20240226","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s10792-016-0183-x","article-title":"Intravitreal bevacizumab and feeder vessel laser treatment for a posteriorly located retinal capillary hemangioma","volume":"36","author":"Agarwal","year":"2016","journal-title":"Int Ophthalmol"},{"key":"R2-20240226","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ophtha.2007.03.009","article-title":"Clinical characterization of retinal capillary hemangiomas in a large population of patients with von Hippel-Lindau disease","volume":"115","author":"Wong","year":"2008","journal-title":"Ophthalmology"},{"key":"R3-20240226","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1056\/NEJMc0708819","article-title":"Propranolol for severe hemangiomas of infancy","volume":"358","author":"L\u00e9aut\u00e9-Labr\u00e9ze","year":"2008","journal-title":"N Engl J Med"},{"key":"R4-20240226","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1111\/bjd.12189","article-title":"Propranolol in a case series of 174 patients with complicated infantile haemangioma: indications, safety and future directions","volume":"168","author":"Hermans","year":"2013","journal-title":"Br J Dermatol"},{"key":"R5-20240226","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1365-2133.2010.09848.x","article-title":"Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action","volume":"163","author":"Storch","year":"2010","journal-title":"Br J Dermatol"},{"key":"R6-20240226","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.preteyeres.2014.06.001","article-title":"The \u03b2-adrenergic system as a possible new target for pharmacologic treatment of neovascular retinal diseases","volume":"42","author":"Casini","year":"2014","journal-title":"Prog Retin Eye Res"},{"key":"R7-20240226","doi-asserted-by":"crossref","first-page":"8228","DOI":"10.1167\/iovs.15-17169","article-title":"Ocular safety of intravitreal propranolol and its efficacy in attenuation of choroidal neovascularization","volume":"56","author":"Nourinia","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R8-20240226","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1167\/iovs.16-20204","article-title":"\u03b22\u2013adrenergic receptor antagonism attenuates CNV through inhibition of VEGF and IL-6 expression\u03b22-adrenergic receptor and exudative AMD","volume":"58","author":"Lavine","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R9-20240226","first-page":"48","article-title":"Therapeutic options for capillary papillary hemangiomas","volume":"107","author":"Garcia-Arumi","year":"2000","journal-title":"Ophthalmology"},{"key":"R10-20240226","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrc885","article-title":"Molecular basis of the VHL hereditary cancer syndrome","volume":"2","author":"Kaelin","year":"2002","journal-title":"Nat Rev Cancer"}],"container-title":["RETINAL Cases &amp; Brief Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/ICB.0000000000000718","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T21:01:02Z","timestamp":1708981262000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/ICB.0000000000000718"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/icb.0000000000000718","relation":{},"ISSN":["1935-1089"],"issn-type":[{"value":"1935-1089","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]}}}